NCT01410474

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan

A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 341 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 2 Years – 18 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the immunogenicity and safety of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from 2 to 18 years in Taiwan.

Conditions

• Bacterial Meningitis

Interventions

Type	Name	Description
BIOLOGICAL	Meningococcal ACWY conjugate vaccine	All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2011-08-05
• Last updated: 2014-09-22
• Results posted: 2014-09-22

Locations

3 sites across 1 country: China